Adicet Bio (ACET) vs China Pharma (CPHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
China Pharma (CPHI) has outperformed Adicet Bio (ACET) over the past year, losing 72.6% versus a loss of 77.8%. Over five years, ACET leads with a -98.6% price change compared with -99.8% for CPHI. Adicet Bio is the larger company by market cap ($20.0 million vs $18.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | CPHI |
|---|---|---|
| Share price | $2.14 | $0.4384 |
| Market cap | $20.03M | $18.86M |
| 1-day change | -13.01% | -13.00% |
| YTD return | -74.58% | -63.77% |
| 1-year return | -77.78% | -72.60% |
| 5-year return | -98.58% | -99.84% |
| EPS (TTM) | $-7.53 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.14M |
| Revenue growth (YoY) | — | -8.49% |
| Net income (latest FY) | $-116.80M | $-3.19M |
| Gross margin | — | -3.18% |
| Operating margin | — | -78.16% |
| Net margin | — | -76.91% |
| 52-week high | $11.15 | $19.19 |
| 52-week low | $2.12 | $0.38 |
| Distance from 52-week high | -80.81% | -97.72% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1527.57% | — |
| Average volume | 271.05K | 1.60M |
| Shares outstanding | 9.36M | 43.02M |
| Employees | 102 | 215 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
ACET vs CPHI FAQ
Which is bigger, Adicet Bio or China Pharma?
Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.86M for China Pharma (CPHI).
Which stock has performed better over the past year, ACET or CPHI?
CPHI returned -72.60% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and China Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.